ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2100

Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus

Samantha Chalmers1, Sayra Garcia1, Andrew Draganski1, Jessica Doerner2, Adam Friedman3, Joel Friedman1 and Chaim Putterman4, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Pennsylvania, Philadelphia, PA, 3Dermatology, GW School of Medicine and Health Sciences, Washington, DC, 4Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cutaneous lupus, Lesions, Lupus, skin and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Cutaneous lupus erythematosus (CLE) affects ~75% of SLE patients and has a profound impact on quality of life. While the morbidity from CLE is significant, effective therapeutic options, including topical therapies, are limited. There is growing evidence that the manipulation of the endocannabinoid system has immunomodulatory activity which could be clinically translated to a broad range of cutaneous and systemic inflammatory diseases, although data is limited especially with respect to topical administration. In this study, local application of anandamide (AEA), a highly lipophilic endocannabinoid, was evaluated in MRL/lpr lupus prone mice, which spontaneously develop skin lesions similar to chronic CLE both clinically and histologically. To overcome known issues with respect to topical delivery of cannabinoids, nanoparticle encapsulation was employed.

Methods:

Nanoparticles with 125 nm radius were loaded with 4% AEA (AEA-np) and mixed with coconut oil (25% by weight). Starting at 10 weeks of age, female MRL/lpr mice were treated twice a week with interscapular application of the AEA compound without hair removal. Control groups of mice were treated topically with empty nanoparticles (“control treated”) or received only coconut oil (“untreated”). Mice were regularly scored using a validated modified CLASI tool to assess the effect of AEA on cutaneous disease. At 20 weeks of age, mice were sacrificed and the skin harvested for histological analysis.  

Results:

AEA-np treated mice had significantly improved skin lesions. Interestingly, this improvement was noted both where the nanoparticles were directly applied, as well as the face/snout region. At the time of sacrifice, AEA treated mice had significantly less macroscopic lesions (Figure 1A), which were scored blindly (p<0.0001) (Figure 1B). Moreover, significant histologic improvement was seen as well (p<0.05; Figure 1C). No differences were seen in systemic disease parameters, namely circulating anti-dsDNA antibodies and proteinuria levels. Immunofluorescent staining of skin sections to characterize cellular infiltration and mechanistic studies in vitro are in progress.

Conclusion:

Together, these data demonstrate that topical administration with AEA loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. Furthermore, this work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases.

Figure 1


Disclosure: S. Chalmers, None; S. Garcia, None; A. Draganski, None; J. Doerner, None; A. Friedman, Zylo Therapuetics, 5; J. Friedman, Zylo Therapuetics, 5; C. Putterman, None.

To cite this abstract in AMA style:

Chalmers S, Garcia S, Draganski A, Doerner J, Friedman A, Friedman J, Putterman C. Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/topical-endocannabinoid-administration-protects-mrl-lpr-lpr-mice-from-cutaneous-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/topical-endocannabinoid-administration-protects-mrl-lpr-lpr-mice-from-cutaneous-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology